Your browser doesn't support javascript.
loading
The Influence of Multiple-Dose Vorapaxar, an Oral PAR-1 Receptor Antagonist, on the Single-Dose Pharmacokinetics and Pharmacodynamics of Digoxin.
Kosoglou, Teddy; Zhu, Yali; Statkevich, Paul; Xuan, Fengjuan; Schiller, James E; Johnson-Levonas, Amy O; Cutler, David L.
Affiliation
  • Kosoglou T; Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
  • Zhu Y; Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
  • Statkevich P; Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
  • Xuan F; Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
  • Schiller JE; Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
  • Johnson-Levonas AO; Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
  • Cutler DL; Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA.
Clin Pharmacol Drug Dev ; 2(1): 90-8, 2013 Jan.
Article in En | MEDLINE | ID: mdl-27121563
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Pharmacol Drug Dev Year: 2013 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Clin Pharmacol Drug Dev Year: 2013 Document type: Article Affiliation country: United States Country of publication: United States